US20040062736A1 - Hair growth promoter - Google Patents
Hair growth promoter Download PDFInfo
- Publication number
- US20040062736A1 US20040062736A1 US10/665,857 US66585703A US2004062736A1 US 20040062736 A1 US20040062736 A1 US 20040062736A1 US 66585703 A US66585703 A US 66585703A US 2004062736 A1 US2004062736 A1 US 2004062736A1
- Authority
- US
- United States
- Prior art keywords
- hair
- group
- pyridine
- phenyl
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 15
- 239000007952 growth promoter Substances 0.000 title 1
- 210000004209 hair Anatomy 0.000 claims abstract description 85
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 201000004384 Alopecia Diseases 0.000 claims abstract description 13
- 230000003676 hair loss Effects 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 11
- 230000012010 growth Effects 0.000 claims abstract description 9
- 230000001548 androgenic effect Effects 0.000 claims abstract description 7
- 230000003247 decreasing effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 5
- 210000004761 scalp Anatomy 0.000 claims description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- OXEIXRNCCWLEFR-UHFFFAOYSA-N 3-(pyridin-3-yldiazenyl)pyridine-2,6-diamine Chemical compound NC1=NC(N)=CC=C1N=NC1=CC=CN=C1 OXEIXRNCCWLEFR-UHFFFAOYSA-N 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 230000001256 tonic effect Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- -1 R2 is H Chemical group 0.000 claims description 4
- BZFVAFGDLPUGQE-UHFFFAOYSA-N NC1=[N+]([O-])C(N)=CC=C1N=NC1=CC=CN=C1 Chemical compound NC1=[N+]([O-])C(N)=CC=C1N=NC1=CC=CN=C1 BZFVAFGDLPUGQE-UHFFFAOYSA-N 0.000 claims description 4
- 229910004727 OSO3H Inorganic materials 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- OBALXRICACMMGD-UHFFFAOYSA-N 4-[2-nitro-4-(trifluoromethyl)phenyl]but-3-ene-1,2-diol Chemical compound OCC(O)C=CC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O OBALXRICACMMGD-UHFFFAOYSA-N 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000003780 hair follicle Anatomy 0.000 description 20
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000002304 perfume Substances 0.000 description 12
- 235000015961 tonic Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 0 *.*C.*C.*C.C1=CC=CC=C1.C1=CC=NC=C1.C1=CSC=C1.C1=CSC=N1.CC.CC.CC.CC Chemical compound *.*C.*C.*C.C1=CC=CC=C1.C1=CC=NC=C1.C1=CSC=C1.C1=CSC=N1.CC.CC.CC.CC 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- SMFFZOQLHYIRDA-UHFFFAOYSA-N 3,4-dimethoxyphenol Chemical compound COC1=CC=C(O)C=C1OC SMFFZOQLHYIRDA-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 241000086254 Arnica montana Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Chemical compound OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- YBPAYPRLUDCSEY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=C(O)C=C1 YBPAYPRLUDCSEY-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- VMJOFTHFJMLIKL-UHFFFAOYSA-N 2-thiophen-2-ylethanol Chemical compound OCCC1=CC=CS1 VMJOFTHFJMLIKL-UHFFFAOYSA-N 0.000 description 1
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 1
- HAQLHRYUDBKTJG-UHFFFAOYSA-N 3,5-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=CC(C=O)=C1 HAQLHRYUDBKTJG-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N N-acetyl-para-amino-phenol Natural products CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- CISGOYZPEUEFIW-UHFFFAOYSA-N OC1=CC=C(F)C=C1.OCCOC1=CC=CC=C1O Chemical compound OC1=CC=C(F)C=C1.OCCOC1=CC=CC=C1O CISGOYZPEUEFIW-UHFFFAOYSA-N 0.000 description 1
- FCKLFGKATYPJPG-SSTBVEFVSA-N Oxendolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 FCKLFGKATYPJPG-SSTBVEFVSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940127343 Potassium Channel Agonists Drugs 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 1
- VFGRALUHHHDIQI-UHFFFAOYSA-N butyl 2-hydroxyacetate Chemical compound CCCCOC(=O)CO VFGRALUHHHDIQI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QPAXMPYBNSHKAK-UHFFFAOYSA-N chloro(difluoro)methane Chemical compound F[C](F)Cl QPAXMPYBNSHKAK-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229950006827 oxendolone Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004584 polyacrylic acid Chemical class 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- ZZPKZRHERLGEKA-UHFFFAOYSA-N resorcinol monoacetate Chemical compound CC(=O)OC1=CC=CC(O)=C1 ZZPKZRHERLGEKA-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/418—Amines containing nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Definitions
- the present invention relates to an agent for promoting the growth of hair and/or decreasing hair fall-out, containing particular cyclic compounds, and to a method for decreasing hair fall-out and for promoting hair growth.
- the human scalp normally harbors 100,000 to 150,000 hair follicles or hairs.
- the hair follicles or hair roots or hair bulbi are the hair-forming organs.
- the long, strong hairs, which build up the hair coverage of the head, are referred to as terminal hairs.
- the very fine, very short hairs, barely protruding over the surface of the skin, at the edges of the head of hair coverage or on the forehead, are referred to as fuzz hair or as vellus hair.
- the growth of hair is not continuous, but cyclical.
- the telogen follicle awakens to a new activity or commences a new anagen, in the course of which a new hair grows and the existing club hair is shed.
- This hair growth cycle proceeds unchanged during the whole of life and, moreover equally in the case of the long, strong terminal hair as well as in the case of the very short fuzz hair or vellus hair.
- a prerequisite for a normal growth of a healthy head of hair is a perfectly functioning organism and an optimum supply for it of all the necessary nutrients and auxiliary materials.
- Many factors can affect the growth of the hair on the head, namely wrong nutrition, deficient nutrition, severe illnesses, medicinal drugs, emotional stresses and temporary disorders of the hormone balance in the organism.
- the form of the hair, the terminal hair or the fuzz hair, or also the hair forms, which lie between the terminal hair and the fuzz hair, which form the hair follicles in the course of life, depends to a large degree on the genetic disposition or the hereditary factors inherent in the hair follicles, as well as on the male sexual hormones.
- the terminal hair follicles in the scalp commence to change over into vellus hair follicles in the course of puberty.
- This conversion process can proceed to very different extents, resulting in scalp regions, which are partially, predominantly or completely covered with fuzz hair follicles or fuzz hair, or partially have the androgenic baldness of the male type (male baldness).
- the male loss of hair is an irreversible form of the loss of hair, unless means are found, which could retard, stop or reverse the transformation of terminal hair follicles into fuzz hair follicles or, in the latter case, transform fuzz hair follicles back into terminal hair follicles.
- Minoxidil the 5-alpha-reductase inhibitor Finasterid (propecia) have been described repeatedly and are said to retard or, to a limited extent, stop or also reverse the conversion of terminal hair follicles into fuzz hair follicles.
- Minoxidil an antihypertensive drug, when administered perorally, promotes on the greater part of the skin to a very pronounced extent the conversion of fuzz hair follicles into terminal hair follicles; however, on the scalp, the corresponding effect is only very weak and from cosmetic points of view, of only a very limited extent, this state of affairs practically being unchanged when the Minoxidil is applied epicutaneously on the scalp.
- Finasterid when administered perorally, is able to inhibit, stop or reverse the transformation of terminal hair follicles into vellus hair follicles to a limited extent.
- this effect is also not satisfactory from every point of view.
- the object of the present invention therefore is an agent for promoting the growth of hair and/or decreasing the falling out of hair with a content of at least one of the compounds of formula (I), (II) and/or (III) or their physiologically tolerated salts,
- a and B independently of one another represent a CH group or a nitrogen atom, at least one of the two groups A and B representing a CH group,
- Y represents —O—, —(CH 2 ) n —, —NH—CH 2 —, —CH 2 —NH—, —NH—CH 2 —, —N ⁇ N—, —CH ⁇ CH—, —CH 2 —O—, O—CH 2 —, —N ⁇ CH—, —CH ⁇ N, —(CH 2 —CH 2 —O) m — or —(O—CH 2 —CH 2 ) m —, with m and n equal to a whole number from 1 to 4,
- Z represents —NH—CH 2 —, —CH 2 —CH 2 —, —CH ⁇ CH— or —CH 2 —NH—,
- R1 is —H, —OH or a C 1 to C 4 hydroxyalkyl group
- R2 is H, cyclopropyl or a C 1 to C 4 alkyl group
- R is NO 2 , SO 2 CH 3 , CF 3 , CHF 2 , F, Cl
- R4, R5, R6 independently of one another are —NO 2 , —CF 3 , —CHF 2 , —F, —Cl, —Br or —H,
- R7 is OH, —OSO 3 H, —O—(C 1 to C 4 alkyl) or —OCOCH 3 ,
- R8 is a C 1 to C 6 alkyl group, a C 1 to C 6 hydroxyalkyl group, a C 2 to C 6 hydroxy-alkenyl group, an aryl group, a heteroaryl group or a C 2 to C 6 alkenyl carboxylic acid group.
- A is —CH— and B is —CH— or —N—
- Y is —N ⁇ N—, —(CH 2 ) n —, —CH ⁇ CH—, —CH ⁇ N— or N ⁇ CH—
- R7 is —OH, —OSO 3 H or —O—(C 1 to C 4 alkyl) and R8 is a C 1 to C 6 alkyl group, a C 1 to C 6 hydroxyalkyl group, a phenyl group, a benzyl group or a pyridyl group
- compounds of formula (III) in which A and B are —CH—, Y is —N ⁇ N—, R7 is —OH (including the corresponding tautomeric N-oxides) and R8 is a pyridyl group, being particularly preferred.
- agents which contain one or more of the following compounds: 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)amino)-3-chloro-2-hydroxy-propane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy-2-trifluoromethyl-ethane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-dihydroxypropane, 1-(2′-nitro-4′-trifluoromethyl-phenyl))-3,4-dihydroxy-1-butene, 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and 2,6-diamino-3-((pyridine-3-yl)-azo-)-pyridine-1-oxide.
- inventive cosmetic agent containing at least one compound of formulas (I), (II) and/or (III), may exist in any form suitable for application on hair and the scalp, especially in the form of an aqueous, alcoholic or aqueous alcoholic preparation, such as a solution, gel, cream, emulsion or dispersion.
- blowing agents which are liquefied under pressure, for example, chlorofluoroalkanes such as CCl 3 F, CCl 2 F 2 , C 2 Cl 3 F 3 , CCl 2 F 2 , CHCl 2 F and (CClF 2 ) 2 , highly volatile hydrocarbons, such as n-butane and n-propane, or also dimethyl ether, carbon dioxide, nitrous oxide, nitrogen, methylene chloride and 1,1,1-trichloromethane.
- chlorofluoroalkanes such as CCl 3 F, CCl 2 F 2 , C 2 Cl 3 F 3 , CCl 2 F 2 , CHCl 2 F and (CClF 2 ) 2
- highly volatile hydrocarbons such as n-butane and n-propane, or also dimethyl ether, carbon dioxide, nitrous oxide, nitrogen, methylene chloride and 1,1,1-trichloromethane.
- the forms, in which the inventive, cosmetic agents are prepared may also, in particular, be those, which remain on the hair and the scalp for a longer period of time and comprise, for example, insertion materials, combing gels, hair pomades, hair treatments, hair oils and hair tonics.
- hair tonics as well as so-called “sustained release” preparations, which emit the active ingredient uniformly over a longer period of time or production of the compounds of formulas (I) and (II) as liposomes.
- the total content of compounds of formula (1) and/or (II) in the inventive agent preferably is about 0.001 to 10 percent by weight, an amount of 0.05 to 3 percent by weight being particularly preferred.
- composition of the inventive cosmetic agent represents a mixture of the compounds of formulas (I) and/or (II) with components, which are customary for such agents, such as carriers and additives.
- carrier materials in general those materials come into consideration, which increase the percutaneous absorption of the active ingredients, do not disadvantageously affect the active ingredient components and, at the same time, are harmless with respect to the human skin.
- Such carrier materials are, for example, water, low molecular weight aliphatic alcohols, such as ethanol, propanol and isopropanol, as well as mixtures of these materials.
- mixtures of the aforementioned compounds with 1 to 30 percent by weight of 1,2-propylene glycol are also advantageous.
- carrier compounds or penetration accelerators such as benzyl alcohol, 2-benzyl-oxyethanol, ⁇ -hydroxycarboxylate esters, vanillin, p-hydroxyanisole, 3-hydroxy-4-methoxy-benzaldehyde, 2-phenoxyethanol, salicylaldehyde, 3,5-dihydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 4-hydroxy-phenylacetamide, methyl p-hydroxybenzoate, p-hydroxy-benzaldehyde, m-cresol, hydroquinone monomethyl ether, o-fluorophenol, m-fluorophenol, p-fluorophenol-2-(2′-hydroxyphenoxy)-ethanol, 3,4-methylene-dioxy-phenol, resorcinol monomethyl ether, 3,4-dimethoxy-phenol, 3-trifluoromethyl-phenol, resorcinol monoacetate, eth
- inventive agents may contain additional, known active ingredients, which maintain a healthy growth of hair and/or support or promote the recuperation of hair growth in the case of disorders of a physiological or non-physiological kind, such as Minoxidil, diazoxide, cyclosporin A, diphenylhydantoin, acetazolamide, antiandrogens of a steroidal and nonsteroidal type, such as cyproterone acetate, oxendolone, spirolactone, 5-alpha-reductase inhibitors, selected extracts of natural origin, retinoids, estrogens, vitamins, such as biotin, trace elements, neuropeptides, nutrients, especially of the essential type, cytokins, neurotrophins, neutrophin receptor antagonists, antimicrobial substances, steroidal or non-steroidal anti-inflammatory substances, calcium antagonists or potassium channel openers (potassium channel agonists).
- active ingredients such as Minoxidil, diazoxide, cyclosporin A, diphenyl
- the present invention furthermore relates to a method for treating hair to reduce hair fall-out and promote hair growth, wherein a sufficient amount of the previously described inventive agent, containing at least one compound of formula (I) or (II), in general about 1 to 30 milliliter and preferably 2 to 15 milliliter, is applied on the hair and scalp, the scalp is massaged subsequently preferably for about 1 to 5 minutes, and the agent is left on the hair and the scalp for prolonged period of time, preferably for at least 24 hours.
- a sufficient amount of the previously described inventive agent containing at least one compound of formula (I) or (II), in general about 1 to 30 milliliter and preferably 2 to 15 milliliter, is applied on the hair and scalp, the scalp is massaged subsequently preferably for about 1 to 5 minutes, and the agent is left on the hair and the scalp for prolonged period of time, preferably for at least 24 hours.
- the treatment is carried out once or twice daily and for a period of 3 to 24 months.
- the interval between applications can then be increased.
- a further object of the present invention is the use of compounds of formulas (I), (II) and/or (III), alone or in combination with one another, to promote hair growth and/or to decrease androgenic loss of hair.
- the above hair tonic (in each case 10 milliliters) is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minutes.
- the above hair tonic (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minutes.
- the above hair treatment (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the hair treatment is rinsed out with lukewarm water.
- the above hair tonic (in each case 10 milliliters) is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minute.
- the above hair tonic (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minute.
- the above hair treatment (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the hair treatment is rinsed out with lukewarm water.
- the above hair growth agent (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minute. After a period of action of about 24 hours, the agent is rinsed out with lukewarm water.
- the above hair growth agent (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the agent is rinsed out with lukewarm water.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an agent for promoting the growth of hair and decreasing hair fall-out containing compounds of formulas (I), (II) and/or (III)
a method for reducing the loss of hair and for promoting the growth of hair by using this agent and to the use of the compounds of formulas (I), (II) and/or (III) for promoting hair growth and/or reducing androgenic loss of hair.
Description
- The present invention relates to an agent for promoting the growth of hair and/or decreasing hair fall-out, containing particular cyclic compounds, and to a method for decreasing hair fall-out and for promoting hair growth.
- The human scalp normally harbors 100,000 to 150,000 hair follicles or hairs. The hair follicles or hair roots or hair bulbi are the hair-forming organs. The long, strong hairs, which build up the hair coverage of the head, are referred to as terminal hairs. The very fine, very short hairs, barely protruding over the surface of the skin, at the edges of the head of hair coverage or on the forehead, are referred to as fuzz hair or as vellus hair. The growth of hair is not continuous, but cyclical. Three growth phases are identified: (1) the anagen, during which the hair grows, (2) the katagen, during which the hair follicle prepares for the next phase, the telogen, and the previously growing hair is converted into a resting hair or club hair and (3) the telogen, that is, the resting phase, during which hair growth ceases completely. In response to a signal, which is not identified at the present time, the telogen follicle awakens to a new activity or commences a new anagen, in the course of which a new hair grows and the existing club hair is shed. This hair growth cycle proceeds unchanged during the whole of life and, moreover equally in the case of the long, strong terminal hair as well as in the case of the very short fuzz hair or vellus hair. A prerequisite for a normal growth of a healthy head of hair is a perfectly functioning organism and an optimum supply for it of all the necessary nutrients and auxiliary materials. Many factors can affect the growth of the hair on the head, namely wrong nutrition, deficient nutrition, severe illnesses, medicinal drugs, emotional stresses and temporary disorders of the hormone balance in the organism. A loss of hair, brought about by such factors, usually is temporary.
- The form of the hair, the terminal hair or the fuzz hair, or also the hair forms, which lie between the terminal hair and the fuzz hair, which form the hair follicles in the course of life, depends to a large degree on the genetic disposition or the hereditary factors inherent in the hair follicles, as well as on the male sexual hormones. In persons with the hereditary factors to male or androgenic loss of hair, the terminal hair follicles in the scalp commence to change over into vellus hair follicles in the course of puberty. This conversion process can proceed to very different extents, resulting in scalp regions, which are partially, predominantly or completely covered with fuzz hair follicles or fuzz hair, or partially have the androgenic baldness of the male type (male baldness). The male loss of hair is an irreversible form of the loss of hair, unless means are found, which could retard, stop or reverse the transformation of terminal hair follicles into fuzz hair follicles or, in the latter case, transform fuzz hair follicles back into terminal hair follicles.
- In the literature, materials, such as Minoxidil, the 5-alpha-reductase inhibitor Finasterid (propecia) have been described repeatedly and are said to retard or, to a limited extent, stop or also reverse the conversion of terminal hair follicles into fuzz hair follicles. Admittedly, Minoxidil, an antihypertensive drug, when administered perorally, promotes on the greater part of the skin to a very pronounced extent the conversion of fuzz hair follicles into terminal hair follicles; however, on the scalp, the corresponding effect is only very weak and from cosmetic points of view, of only a very limited extent, this state of affairs practically being unchanged when the Minoxidil is applied epicutaneously on the scalp. Admittedly, Finasterid, when administered perorally, is able to inhibit, stop or reverse the transformation of terminal hair follicles into vellus hair follicles to a limited extent. However, from cosmetics points of view, this effect is also not satisfactory from every point of view.
- Since far more than half the men and, to an increasing extent, also women are affected by loss of hair, there is a great demand for materials, which are able to inhibit, stop or even reverse hair falling out, especially in men, in all its outward appearances.
- Surprisingly, it has now been found that certain benzene derivatives of formula (I) and heteroaromatic compounds of formula (II), alone or in combination with one another, applied epicutaneously on the scalp, can decisively improve the hair falling out phenomenon especially in men, the conversion of terminal hair follicles into vellus hair follicles being retarded, stopped or even reversed.
-
- in which the groups A, B, Y, Z and R1 to R8 independently of one another have the following meaning:
- A and B independently of one another represent a CH group or a nitrogen atom, at least one of the two groups A and B representing a CH group,
- Y represents —O—, —(CH2)n—, —NH—CH2—, —CH2—NH—, —NH—CH2—, —N═N—, —CH═CH—, —CH2—O—, O—CH2—, —N═CH—, —CH═N, —(CH2—CH2—O)m— or —(O—CH2—CH2)m—, with m and n equal to a whole number from 1 to 4,
- Z represents —NH—CH2—, —CH2—CH2—, —CH═CH— or —CH2—NH—,
- R1 is —H, —OH or a C1 to C4 hydroxyalkyl group,
- R2 is H, cyclopropyl or a C1 to C4 alkyl group,
-
- (in which R is NO2, SO2CH3, CF3, CHF2, F, Cl),
- R4, R5, R6 independently of one another are —NO2, —CF3, —CHF2, —F, —Cl, —Br or —H,
- R7 is OH, —OSO3H, —O—(C1 to C4 alkyl) or —OCOCH3,
- R8 is a C1 to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a C2 to C6 hydroxy-alkenyl group, an aryl group, a heteroaryl group or a C2 to C6 alkenyl carboxylic acid group.
-
- C1 to C2 hydroxyalkyl group, —CH2—X (with X=F, Cl Br or I), —CF3 or —CH3 and R4, R5, R6 independently of one another are —NO2, —CF3, —CHF2, —CH2F, —F, —Cl, —Br or —H; compounds of formula (I), in which Z represents —NH—CH2—, —CH2—CH2—, —CH═CH— or —CH2—NH—, R1 represents —OH or —CH2OH; R2 represents —H or —CH3, R3 represents a C1 to C2 hydroxyalkyl group, —CH2—X (with X=F, Cl Br or I), —CF3 or —CH3 and, independently of one another, R4 represents —NO2, R5 represents —CF3 and R6 represents —H and especially compounds of Formula (I) in which Z represents —NH—CH2—, R1 represents —OH, R2 represents —H, R3 represents —CH2OH, R4 represents —NO2, R5 represents —CF3 and R6 represents —H are particularly preferred.
- Also preferred are compounds of formula (II) in which A represents —CH— and B represents —CH— or —N, Y represents —N═N—, —(CH2)n—, —CH═CH, —CH═N— or —N═CH— and R8 a C1 to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a phenyl group, a benzyl group or a pyridyl group, compounds of formula (II) in which A and B represent —CH—, Y represents —N═N— and R8 represents a pyridyl group, being particularly preferred.
- Also preferred are compounds of formula (III) in which A is —CH— and B is —CH— or —N—, Y is —N═N—, —(CH2)n—, —CH═CH—, —CH═N— or N═CH—, R7 is —OH, —OSO3H or —O—(C1 to C4 alkyl) and R8 is a C1 to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a phenyl group, a benzyl group or a pyridyl group, compounds of formula (III), in which A and B are —CH—, Y is —N═N—, R7 is —OH (including the corresponding tautomeric N-oxides) and R8 is a pyridyl group, being particularly preferred.
- Especially preferred here are those agents, which contain one or more of the following compounds: 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)amino)-3-chloro-2-hydroxy-propane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy-2-trifluoromethyl-ethane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-dihydroxypropane, 1-(2′-nitro-4′-trifluoromethyl-phenyl))-3,4-dihydroxy-1-butene, 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and 2,6-diamino-3-((pyridine-3-yl)-azo-)-pyridine-1-oxide. Of these compounds, especially 1-(N-(2′-nitro-4′-trifluoromethylphenyl)-amino)-2,3-propylene glycol and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and combinations of these compounds are named.
- The inventive cosmetic agent, containing at least one compound of formulas (I), (II) and/or (III), may exist in any form suitable for application on hair and the scalp, especially in the form of an aqueous, alcoholic or aqueous alcoholic preparation, such as a solution, gel, cream, emulsion or dispersion. It is also possible to dispense these agents as a spray or a foam from a pressurized container with conventional blowing agents, which are liquefied under pressure, for example, chlorofluoroalkanes such as CCl3F, CCl2F2, C2Cl3F3, CCl2F2, CHCl2F and (CClF2)2, highly volatile hydrocarbons, such as n-butane and n-propane, or also dimethyl ether, carbon dioxide, nitrous oxide, nitrogen, methylene chloride and 1,1,1-trichloromethane.
- The forms, in which the inventive, cosmetic agents are prepared, may also, in particular, be those, which remain on the hair and the scalp for a longer period of time and comprise, for example, insertion materials, combing gels, hair pomades, hair treatments, hair oils and hair tonics. Especially preferred in this connection are hair tonics as well as so-called “sustained release” preparations, which emit the active ingredient uniformly over a longer period of time or production of the compounds of formulas (I) and (II) as liposomes.
- The total content of compounds of formula (1) and/or (II) in the inventive agent preferably is about 0.001 to 10 percent by weight, an amount of 0.05 to 3 percent by weight being particularly preferred.
- The composition of the inventive cosmetic agent represents a mixture of the compounds of formulas (I) and/or (II) with components, which are customary for such agents, such as carriers and additives.
- As carriers, in general those materials come into consideration, which increase the percutaneous absorption of the active ingredients, do not disadvantageously affect the active ingredient components and, at the same time, are harmless with respect to the human skin. Such carrier materials are, for example, water, low molecular weight aliphatic alcohols, such as ethanol, propanol and isopropanol, as well as mixtures of these materials. However, mixtures of the aforementioned compounds with 1 to 30 percent by weight of 1,2-propylene glycol are also advantageous.
- The following come into consideration as conventional additives in the inventive cosmetic agents: carrier compounds or penetration accelerators, such as benzyl alcohol, 2-benzyl-oxyethanol, α-hydroxycarboxylate esters, vanillin, p-hydroxyanisole, 3-hydroxy-4-methoxy-benzaldehyde, 2-phenoxyethanol, salicylaldehyde, 3,5-dihydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 4-hydroxy-phenylacetamide, methyl p-hydroxybenzoate, p-hydroxy-benzaldehyde, m-cresol, hydroquinone monomethyl ether, o-fluorophenol, m-fluorophenol, p-fluorophenol-2-(2′-hydroxyphenoxy)-ethanol, 3,4-methylene-dioxy-phenol, resorcinol monomethyl ether, 3,4-dimethoxy-phenol, 3-trifluoromethyl-phenol, resorcinol monoacetate, ethylvanillin, 2-thiophenethanol, butyl lactate and butyl glycolate; thickeners, such as kaolin, bentonite, fatty acids, higher fatty alcohols, starch, polyacrylic acid, cellulose derivatives, alginates, Vaseline or paraffin oil; compounds from the classes of the anionic, cationic, amphoteric, zwitterionic or nonionic surfactants or surface active agents, such as fatty alcohol sulfates, alkyl sulfonates, alkylbenzene sulfates, quaternary ammonium salts, alkyl betaines and ethoxylated esters of fatty acids; furthermore, opacifiers, such as polyethylene glycol esters, foam stabilizers, sequestering agents, buffers, preservatives, solubilizers, perfume oils, natural or synthetic cosmetic polymers, such as cellulose derivatives, shellac, pectins, polyvinylpyrrolidone, polyvinyl acetate, polyacrylic compounds, such as acrylic acid or methacrylic acid polymers, basic polymers of esters of acrylic acid or methacrylic acid with aminealcohols, polyacrylonitrile and chitosan derivatives, hair conditioners, active ingredients against dandruff, plant extracts as well as hair-care components, such as protein hydrolysates, lanolin derivatives, cholesterol, pantothenic acid or betaine.
- Of course, the inventive agents may contain additional, known active ingredients, which maintain a healthy growth of hair and/or support or promote the recuperation of hair growth in the case of disorders of a physiological or non-physiological kind, such as Minoxidil, diazoxide, cyclosporin A, diphenylhydantoin, acetazolamide, antiandrogens of a steroidal and nonsteroidal type, such as cyproterone acetate, oxendolone, spirolactone, 5-alpha-reductase inhibitors, selected extracts of natural origin, retinoids, estrogens, vitamins, such as biotin, trace elements, neuropeptides, nutrients, especially of the essential type, cytokins, neurotrophins, neutrophin receptor antagonists, antimicrobial substances, steroidal or non-steroidal anti-inflammatory substances, calcium antagonists or potassium channel openers (potassium channel agonists).
- The present invention furthermore relates to a method for treating hair to reduce hair fall-out and promote hair growth, wherein a sufficient amount of the previously described inventive agent, containing at least one compound of formula (I) or (II), in general about 1 to 30 milliliter and preferably 2 to 15 milliliter, is applied on the hair and scalp, the scalp is massaged subsequently preferably for about 1 to 5 minutes, and the agent is left on the hair and the scalp for prolonged period of time, preferably for at least 24 hours.
- Preferably, the treatment is carried out once or twice daily and for a period of 3 to 24 months. Optionally, the interval between applications can then be increased.
- A further object of the present invention is the use of compounds of formulas (I), (II) and/or (III), alone or in combination with one another, to promote hair growth and/or to decrease androgenic loss of hair. The use of one or more compounds from the group consisting of 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-3-chloro-2-hydroxy-propane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy-2-tri-fluoromethylethane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-propylene glycol, 1-(2′-nitro-4′-trifluoro-methyl-phenyl)-3,4-dihydroxy-1-butene, 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine-1-oxide. Of these compounds, especially 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-propylene glycol and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine is particularly preferred for promoting hair growth and/or decreasing androgenic loss of hair.
- The invention is explained in greater detail by means of the following examples, without being limited to these.
- 1.0 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-propylene glycol
1.0 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 3.0 g 1,2-propylene glycol 0.3 g perfume oil to 100.0 g ethanol (96%) - In each case, 15 milliliters of the above hair tonic are applied once daily (every 24 hours) on the hair and the scalp and massaged into the scalp for 1 minute.
-
2.0 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 1.0 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 0.1 g menthol 0.3 g perfume oil to 100.0 g ethanol (96%) - The above hair tonic is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minutes.
-
0.30 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.05 g polyvinylpyrrolidone 0.10 g Arnika tincture 0.30 g perfume oil to 100.00 g ethanol (96%) - The above hair tonic (in each case 10 milliliters) is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minutes.
-
1.0 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.5 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 0.2 g hydrogenated castor oil with 60 moles of ethylene oxide (Chremophor RH 60 of BASF AG/Ludwigshafen 0.3 g perfume oil 40.0 g ethanol (96%) to 100.0 g water - The above hair tonic (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minutes.
-
0.4 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.2 g hydrogenated castor oil with 60 moles of ethylene oxide (Chremophor RH 60 of BASF AG/Ludwigshafen 0.3 g perfume oil 0.5 g cetyl alcohol to 100.0 g water - The above hair treatment (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the hair treatment is rinsed out with lukewarm water.
-
1.0 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-3-chloro-2- hydroxy-propane 1.0 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 3.0 g 1,2-propylene glycol 0.3 g perfume oil to 100.0 g ethanol (96%) - In each case, 15 milliliters of the above hair tonic are applied once daily (every 24 hours) on the hair and the scalp and massaged into the scalp for 1 minute.
-
2.0 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy- 2-trifluoro-methylethane 1.0 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 0.1 g menthol 0.3 g perfume oil to 100.0 g ethanol (96%) - The above hair tonic is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minutes.
-
0.30 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-1-butene- 3,4-diol 0.05 g polyvinylpyrrolidone 0.10 g Arnika tincture 0.3 g perfume oil to 100.0 g ethanol (96%) - The above hair tonic (in each case 10 milliliters) is applied twice daily on the hair and the scalp and massaged into the scalp for 2 minute.
-
0.7 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.9 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine-1-oxide 0.2 g hydrogenated castor oil with 60 moles of ethylene oxide (Chremophor RH 60 of BASF AG/Ludwigshafen 0.3 g perfume oil 50.0 g ethanol (96%) to 100.0 g water - The above hair tonic (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minute.
-
0.3 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.01 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine-1-oxide 0.2 g hydrogenated castor oil with 60 moles of ethylene oxide (Chremophor RH 60 of BASF AG/Ludwigshafen 0.3 g perfume oil 0.5 g cetyl alcohol to 100.0 g ethanol (96%) - The above hair treatment (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the hair treatment is rinsed out with lukewarm water.
-
0.4 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3- propylene glycol 0.1 g 2,6 diamino-3-((pyridine-3-yl)-azo)-pyridine 30.0 g partially hydrogenated peanut oil (oleum arachidis hydrogenatum) 5.0 g cetyl stearyl alcohol 0.2 g perfume oil 10.0 g propylene glycol to 100.0 g water - The above hair growth agent (in each case 20 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 1 to 2 minute. After a period of action of about 24 hours, the agent is rinsed out with lukewarm water.
- 0.300 g 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-propylene glycol
- 0.560 g carboxyvinyl polymer (Carbopol 940 of BF Goodrich/USA)
- 0.224 g sodium hydroxide to 100.000 g water
- The above hair growth agent (in each case 15 milliliters) is applied once daily on the hair and the scalp and massaged into the scalp for 2 minutes. After a period of action of about 24 hours, the agent is rinsed out with lukewarm water.
- Unless it is stated otherwise, all weight data is given as weight percent.
Claims (11)
1. An agent for promoting the growth of hair and/or decreasing hair fallout, wherein at least one of the compounds of formula (I), (II) and/or (III) or their physiologically tolerated salts,
is contained, in which the groups A, B, Y, Z and R1 to R8 independently of one another have the following meaning:
A and B independently of one another represent a CH group or a nitrogen atom, at least one of the two groups A and B representing a CH group,
Y represents —O—, —(CH2)n—, —NH—CH2—, —CH2—NH—, —NH—CH2—, —N═N—, —CH═CH—, —CH2—O—, O—CH2—, —N═CH—, —CH═N, —(CH2—CH2—O)m— or —(O—CH2—CH2)m—, with m and n equal to a whole number from 1 to 4,
Z represents —NH—CH2—, —CH2—CH2—, —CH═CH— or —CH2—NH—,
R1 is —H, —OH or a C1 to C4 hydroxyalkyl group,
R2 is H, cyclopropyl or a C1 to C4 alkyl group,
R3 is a C1 to C2 hydroxyalkyl group, —CH2—X or —CHX2 (with X=F, Cl, Br or I), —COCH3, —CF3, —CH3 or
R4, R5, R6 independently of one another are —NO2, —CF3, —CHF2, —F, —Cl, —Br or —H,
R7 is OH, —OSO3H, —O—(C1 to C4 alkyl) or —OCOCH3,
R8 is a C1 to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a C2 to C6 hydroxy-alkenyl group, an aryl group, a heteroaryl group or a C2 to C6 alkenyl carboxylic acid group.
2. The agent of claim 1 , wherein the compound of formula (1), in which Z is —NH—CH2—, —CH2—CH2—, —CH═CH— or —CH2—NH—, R1 is —OH, —CH2OH or —CH2CH2OH, R2 is —H, CH3, or —C2H5; R3 is
3. The agent of claim 1 , wherein the compound of formula (II) is selected from compounds of formula (II) in which A represents —CH— or —N, Y represents —N═N—, —(CH2)n—, —CH═CH, —CH—N— or —N═CH— and R8 a C1 to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a phenyl group, a benzyl group or a pyridyl group.
4. The agent of claim 1 , wherein the compound of formula (III) is selected from compounds of formula (III) in which A is —CH— and B is —CH— or —N—, Y is —N═N—, —(CH2)n—, —CH═CH—, —CH═N— or N═CH—, R7 is —OH, —OSO3H or —O—(C1 to C4 alkyl) and R8 is a C, to C6 alkyl group, a C1 to C6 hydroxyalkyl group, a phenyl group, a benzyl group or a pyridyl group.
5. The agent of one of the claims 1 to 4 , wherein the compound of formula (I), (II) and/or (III) is selected from 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-3-chloro-2-hydroxy-propane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy-2-trifluoromethylethane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3′-dihydroxy-propane, 1-(2′-nitro-4′-trifluoromethyl-phenyl))-3,4-dihydroxy-1-butene, 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and 2,6-diamino-3-((pyridine-3-yl)-azo-)-pyridine-1-oxide or combinations of these compounds.
6. The agent of claim 5 , wherein the compound of formula (I), (II) and/or (III) is selected from 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2,3-propylene glycol and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine as well as from the combination of these compounds.
7. The agent of one of the claims 1 to 6 , wherein the compound of formulas (I) and/or (II) are contained in a total amount of 0.001 to 10 percent by weight.
8. The agent of one of the claims 1 to 7 , present in the form of a sustained release preparation or a hair tonic.
9. A hair treatment method for reducing the fall-out of hair and for promoting hair growth, wherein a sufficient amount of an agent of one of the claims 1 to 8 is applied on the hair and the scalp, subsequently the scalp is massaged and the agent is left for at least 24 hours on the hair and the scalp.
10. The use of compounds of formulas (I), (II) and/or (III) for promoting hair growth and/or for reducing the androgenic loss of hair.
11. The use of one or more compounds of the group consisting of 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-3-chloro-2-hydroxy-propane, 1-(N-(2′-nitro-4′-trifluoromethyl-phenyl)-amino)-2-hydroxy-2-trifluoromethylethane, 1-(N-(2′-nitro-4′-tri-fluoromethyl-phenyl)-amino)-2,3-propylene glycol, 1-(2′-nitro-4′-trifluoromethylphenyl)-3,4-dihydroxy-1-butene, 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine-1-oxide. Of these compounds, 1-(N-(2′-nitro-4′-tri-fluoromethyl-phenyl)-amino)-2,3-propylene glycol and 2,6-diamino-3-((pyridine-3-yl)-azo)-pyridine are particularly preferred for promoting hair growth and/or decreasing androgenic loss of hair.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/665,857 US20040062736A1 (en) | 1998-10-01 | 2003-09-19 | Hair growth promoter |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19845202A DE19845202A1 (en) | 1998-10-01 | 1998-10-01 | Hair restorer |
DE19845202.0 | 1998-10-01 | ||
US09/744,892 US6488922B1 (en) | 1998-10-01 | 1999-08-26 | Hair growth promoter |
US10/159,310 US6667028B2 (en) | 1998-10-01 | 2002-05-31 | Hair growth promoter |
US10/665,857 US20040062736A1 (en) | 1998-10-01 | 2003-09-19 | Hair growth promoter |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/159,310 Division US6667028B2 (en) | 1998-10-01 | 2002-05-31 | Hair growth promoter |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040062736A1 true US20040062736A1 (en) | 2004-04-01 |
Family
ID=7883038
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/744,892 Expired - Fee Related US6488922B1 (en) | 1998-10-01 | 1999-08-26 | Hair growth promoter |
US10/159,310 Expired - Lifetime US6667028B2 (en) | 1998-10-01 | 2002-05-31 | Hair growth promoter |
US10/665,857 Abandoned US20040062736A1 (en) | 1998-10-01 | 2003-09-19 | Hair growth promoter |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/744,892 Expired - Fee Related US6488922B1 (en) | 1998-10-01 | 1999-08-26 | Hair growth promoter |
US10/159,310 Expired - Lifetime US6667028B2 (en) | 1998-10-01 | 2002-05-31 | Hair growth promoter |
Country Status (9)
Country | Link |
---|---|
US (3) | US6488922B1 (en) |
EP (2) | EP1426034B1 (en) |
JP (1) | JP2002526392A (en) |
AT (2) | ATE326943T1 (en) |
AU (1) | AU5970999A (en) |
BR (1) | BR9914101A (en) |
DE (3) | DE19845202A1 (en) |
ES (2) | ES2224749T3 (en) |
WO (1) | WO2000019969A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090041770A1 (en) * | 2004-11-12 | 2009-02-12 | Chamberlain Aaron Keith | Fc VARIANTS WITH ALTERED BINDING TO FcRn |
US20100016315A1 (en) * | 2006-10-23 | 2010-01-21 | Masato Yoshida | Iminopyridine Derivative and Use Thereof |
US20110034464A1 (en) * | 2008-04-23 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
US20110039892A1 (en) * | 2008-04-23 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2833489B1 (en) * | 2001-12-18 | 2004-09-03 | Oreal | USE FOR THE TREATMENT OF ELECTROPHILIC MONOMER HAIR |
DE10303509A1 (en) * | 2002-08-23 | 2004-03-04 | Koc, Felix, Dr. | Hair growth promoting composition contains finasteride for oral administration in combination with biotin or for external administration |
US20060148893A1 (en) * | 2003-06-10 | 2006-07-06 | Blanc Jean-Baptiste E | Chemical compounds |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CN103102303B (en) | 2004-12-31 | 2015-10-28 | 雷迪博士实验室有限公司 | As the benzyl amine derivative of CETP inhibitor |
JP2008184423A (en) * | 2007-01-30 | 2008-08-14 | Kao Corp | Hair waving ameliorator |
ES2478823T3 (en) * | 2008-04-23 | 2014-07-23 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
CN102918430B (en) | 2010-06-01 | 2016-08-24 | 3M创新有限公司 | Multi-layer sealed film |
EP2744803A2 (en) | 2011-08-18 | 2014-06-25 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors |
AU2012313971B2 (en) | 2011-09-27 | 2016-09-29 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132106A (en) * | 1989-07-12 | 1992-07-21 | L'oreal | Halogenated pyrimidine 3-oxide derivatives, their use for the treatment and prevention of hair loss and for stimulating its regrowth |
US5328914A (en) * | 1990-07-20 | 1994-07-12 | L'oreal | Use of pyrimidine 3-oxide derivatives for slowing down hair loss and topical compositions used |
US5360804A (en) * | 1990-12-28 | 1994-11-01 | L'oreal | Multicomponent agent or kit for preparing the sulpho-conjugated form of pyridino, pyrimidino or triazino N-oxide compounds and method of use |
US5466694A (en) * | 1991-07-11 | 1995-11-14 | L'oreal | Compositions for slowing down hair loss and for inducing and stimulating its growth, based on 2,4-diamino-pyrimidine 3-oxide derivatives, and new 2,4-diaminopyrimidine 3-oxide derivatives |
US5756092A (en) * | 1995-04-05 | 1998-05-26 | Societel'oreal S.A. | Use, in a composition, as cyclooxygenase activator and/or stabilizer, of at least one pyrimidine derivative sustituted at the 6th position and a cyclooxygenase substrate |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000616A1 (en) * | 1984-07-13 | 1986-01-30 | Gail Sansone Bazzano | Substituted pyrimidine oxides useful for hair growth promotion |
LU87068A1 (en) * | 1987-12-09 | 1989-07-07 | Oreal | COMBINATION OF PYRIMIDINE DERIVATIVES AND CALCIUM ANTAGONISTS FOR INDUCING AND STIMULATING HAIR GROWTH AND REDUCING HAIR LOSS |
US5037446A (en) * | 1987-12-10 | 1991-08-06 | Wella Aktiengesellschaft | 2-nitroaniline derivatives and hair dyeing compositions containing same |
US6291532B1 (en) * | 1996-03-06 | 2001-09-18 | L'oreal | Use of N-aryl-2-hydroxyalkylamides for stimulating or inducing hair growth and/or arresting hair loss |
US6171347B1 (en) * | 1996-11-16 | 2001-01-09 | Wella Aktiengesellschaft | Compositions, methods and kits for reductively removing color from dyed hair |
EP0877593A1 (en) * | 1996-11-28 | 1998-11-18 | Wella Aktiengesellschaft | Agent for dyeing and decolorizing fibers |
DE19712860C1 (en) * | 1997-03-27 | 1998-10-29 | Wella Ag | Powdery agent for making gels |
-
1998
- 1998-10-01 DE DE19845202A patent/DE19845202A1/en not_active Withdrawn
-
1999
- 1999-08-26 JP JP2000573331A patent/JP2002526392A/en active Pending
- 1999-08-26 AT AT04004305T patent/ATE326943T1/en not_active IP Right Cessation
- 1999-08-26 AT AT99970016T patent/ATE270870T1/en not_active IP Right Cessation
- 1999-08-26 US US09/744,892 patent/US6488922B1/en not_active Expired - Fee Related
- 1999-08-26 DE DE59913471T patent/DE59913471D1/en not_active Expired - Lifetime
- 1999-08-26 ES ES99970016T patent/ES2224749T3/en not_active Expired - Lifetime
- 1999-08-26 DE DE59909970T patent/DE59909970D1/en not_active Expired - Fee Related
- 1999-08-26 ES ES04004305T patent/ES2264052T3/en not_active Expired - Lifetime
- 1999-08-26 EP EP04004305A patent/EP1426034B1/en not_active Expired - Lifetime
- 1999-08-26 WO PCT/EP1999/006269 patent/WO2000019969A1/en active IP Right Grant
- 1999-08-26 EP EP99970016A patent/EP1117373B1/en not_active Expired - Lifetime
- 1999-08-26 BR BR9914101-9A patent/BR9914101A/en not_active Application Discontinuation
- 1999-08-26 AU AU59709/99A patent/AU5970999A/en not_active Abandoned
-
2002
- 2002-05-31 US US10/159,310 patent/US6667028B2/en not_active Expired - Lifetime
-
2003
- 2003-09-19 US US10/665,857 patent/US20040062736A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132106A (en) * | 1989-07-12 | 1992-07-21 | L'oreal | Halogenated pyrimidine 3-oxide derivatives, their use for the treatment and prevention of hair loss and for stimulating its regrowth |
US5328914A (en) * | 1990-07-20 | 1994-07-12 | L'oreal | Use of pyrimidine 3-oxide derivatives for slowing down hair loss and topical compositions used |
US5360804A (en) * | 1990-12-28 | 1994-11-01 | L'oreal | Multicomponent agent or kit for preparing the sulpho-conjugated form of pyridino, pyrimidino or triazino N-oxide compounds and method of use |
US5466694A (en) * | 1991-07-11 | 1995-11-14 | L'oreal | Compositions for slowing down hair loss and for inducing and stimulating its growth, based on 2,4-diamino-pyrimidine 3-oxide derivatives, and new 2,4-diaminopyrimidine 3-oxide derivatives |
US5756092A (en) * | 1995-04-05 | 1998-05-26 | Societel'oreal S.A. | Use, in a composition, as cyclooxygenase activator and/or stabilizer, of at least one pyrimidine derivative sustituted at the 6th position and a cyclooxygenase substrate |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090041770A1 (en) * | 2004-11-12 | 2009-02-12 | Chamberlain Aaron Keith | Fc VARIANTS WITH ALTERED BINDING TO FcRn |
US20100016315A1 (en) * | 2006-10-23 | 2010-01-21 | Masato Yoshida | Iminopyridine Derivative and Use Thereof |
US8470859B2 (en) | 2006-10-23 | 2013-06-25 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
US20110034464A1 (en) * | 2008-04-23 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
US20110039892A1 (en) * | 2008-04-23 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU5970999A (en) | 2000-04-26 |
US6488922B1 (en) | 2002-12-03 |
EP1117373A1 (en) | 2001-07-25 |
US6667028B2 (en) | 2003-12-23 |
ATE326943T1 (en) | 2006-06-15 |
ES2224749T3 (en) | 2005-03-01 |
DE19845202A1 (en) | 2000-04-06 |
BR9914101A (en) | 2001-07-31 |
US20030031639A1 (en) | 2003-02-13 |
EP1117373B1 (en) | 2004-07-14 |
EP1426034A1 (en) | 2004-06-09 |
WO2000019969A1 (en) | 2000-04-13 |
ES2264052T3 (en) | 2006-12-16 |
JP2002526392A (en) | 2002-08-20 |
EP1426034B1 (en) | 2006-05-24 |
DE59913471D1 (en) | 2006-06-29 |
ATE270870T1 (en) | 2004-07-15 |
DE59909970D1 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1301653C (en) | Skin treatment composition | |
US6488922B1 (en) | Hair growth promoter | |
EP1269972A1 (en) | Hair growth stimulant compositions with sustained action | |
CA2505500C (en) | Method of stimulating hair growth using benzopyrans | |
US6291532B1 (en) | Use of N-aryl-2-hydroxyalkylamides for stimulating or inducing hair growth and/or arresting hair loss | |
CA2016351C (en) | Cosmetic composition | |
US20090324526A1 (en) | Compositions comprising madecassoside and/or terminoloside and an arginine and/or a salt and/or a derivative thereof for inducing and/or stimulating the growth of human keratin fibers and/or preventing loss thereof | |
JP3045590B2 (en) | Hair restoration cosmetics | |
BRPI0900541B1 (en) | care composition of human keratin fibers, cosmetic use and process of cosmetic treatment of human keratin fibers and / or scalp | |
GB2197589A (en) | Stimulating hair growth | |
JPH0217119A (en) | Pyrimido-(6, 1-a)-isoquinolin-4-one derivative | |
JPH07206647A (en) | Hair tonic | |
JP2862623B2 (en) | Hair restoration | |
EP0333743A1 (en) | Use of nicorandil to treat alopecia | |
JP2002114645A (en) | Hair tonic | |
JP2001122739A (en) | Hair tonic | |
DE29824063U1 (en) | Hair restorer | |
JPH11246363A (en) | Hair grower | |
JPH11106318A (en) | Composition for head | |
JPH07228511A (en) | Hair growing agent | |
JPH07228512A (en) | Hair growing agent | |
JPH04364108A (en) | Hair tonic | |
JPH05124937A (en) | Hair tonic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |